Compared the Efficacy and Safety between Intravenous Vedolizumab and Subcutaneous Formulation Therapy in Inflammatory Bowel Disease: A Meta-Analysis

Traditional treatment method for moderate or severe inflammatory bowel disease (IBD) is intravenous (IV) vedolizumab to suppression α4β7 integrin. This study aims to assess the efficacy and safety of subcutaneous (SC) vedolizumab compared to IV vedolizumab in IBD. We searched PubMed, Embase and Cochrane library. All randomized controlled trials (RCTs) were included, which compared SC vedolizumab to IV vedolizumab treatment in IBD patients. Our main endpoints are remission at week 52, durable remission and treatment-emergent adverse events (TEAEs). The Review Manager 5.4 was used in the meta-analysis. Two RCT studies were included with a total of 172 participants with ulcerative colitis (UC). Two studies (N=172 participants) assessed the odds ratio (OR) of remission at week 52, durable remission and TEAEs during treatment. After analysis, the data of these studies showed there were significant difference in related TEAEs of SC vedolizumab compared with IV vedolizumab treatment (OR=2.48 [95%CI, 1.09-5.61], P=0.03). In both SC and IV vedolizumab treatment, there didn't have death events. And there were no significant difference in clinical remission and endoscopic improvement at week 52 and durable remission (P>0.05). SC vedolizumab treatment has similar efficacy compared to IV vedolizumab treatment in IBD patients. But SC vedolizumab treatment has more related-TEAEs. For safety of SC vedolizumab treatment in IBD patients need further research.